Estrogen receptor subtypes mediate distinct microvascular dilation and reduction in [Ca2+]iin mesenteric microvessels of female rat

Journal of Pharmacology and Experimental Therapeutics

Volumn 352, Issue 2, 2015, Pages 291-304

  Mazzuca, Marc Q ^a   Mata, Karina M ^a,b   Li, Wei ^a,c   Rangan, Sridhar S ^a   Khalil, Raouf A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(2 CHLOROPHENYL)DIPHENYLMETHYL] 1H PYRAZOLE; 1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 1[ 4 [6 BROMO 1,3 BENZODIOXOL 5 YL] 3A,4,5,9B TETRAHYDRO 3H CYCLOPENTA(C) QUINOLIN 8 YL] ETHANONE; 4 AMINOPYRIDINE; 4,4',4'' [4 PROPYL [1H] PYRAZOLE 1,3,5 TRIYL] TRIS PHENOL; ACETYLCHOLINE; APAMIN; CALCIUM ION; DIARYLPROPIONITRILE; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FURA 2; G PROTEIN COUPLED RECEPTOR 30; GLIBENCLAMIDE; IBERIOTOXIN; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; PHENOL DERIVATIVE; PHENYLEPHRINE; POTASSIUM CHANNEL; POTASSIUM CHLORIDE; QUINOLINE DERIVATIVE; RECEPTOR SUBTYPE; TETRYLAMMONIUM; UNCLASSIFIED DRUG; CALCIUM; ESTROGEN;

ANIMAL TISSUE; ARTICLE; BLOOD VESSEL DIAMETER; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; MESENTERY BLOOD VESSEL; MICROVASCULATURE; NONHUMAN; RAT; SPRAGUE DAWLEY RAT; TUNICA MEDIA; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION; AGONISTS; ANIMAL; DRUG EFFECTS; ESTRUS; IN VITRO STUDY; MESENTERIC ARTERY; METABOLISM; MUSCLE CONTRACTION; PHYSIOLOGY;

ANIMALS; CALCIUM; ENDOTHELIUM, VASCULAR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; ESTRUS; FEMALE; IN VITRO TECHNIQUES; MESENTERIC ARTERIES; MICROVESSELS; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; RATS, SPRAGUE-DAWLEY; VASODILATION;

EID: 84919709667     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.219865     Document Type: Article

References (85)

1. Alda JO, Valero MS, Pereboom D, Gros P, and Garay RP (2009) Endotheliumindependent vasorelaxation by the selective alpha estrogen receptor agonist propyl pyrazole triol in rat aortic smooth muscle. J Pharm Pharmacol 61:641-646.
2. Asano M, Aoki K, and Matsuda T (1986) Contractile effects of Bay K 8644, a dihydropyridine calcium agonist, on isolated femoral arteries from spontaneously hypertensive rats. J Pharmacol Exp Ther 239:198-205.
3. Berridge MJ (2008) Smooth muscle cell calcium activation mechanisms. J Physiol 586:5047-5061.
4. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, Parker MA, Tkachenko SE, Savchuck NP, and Sklar LA, et al. (2006) Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2:207-212.
5. Broughton BR, Miller AA, and Sobey CG (2010) Endothelium-dependent relaxation by G protein-coupled receptor 30 agonists in rat carotid arteries. Am J Physiol Heart Circ Physiol 298:H1055-H1061.
6. Busse R, Edwards G, Félétou M, Fleming I, Vanhoutte PM, and Weston AH (2002) EDHF: bringing the concepts together. Trends Pharmacol Sci 23:374-380.
7. Cairrão E, Alvarez E, Carvas JM, Santos-Silva AJ, and Verde I (2012) Non-genomic vasorelaxant effects of 17β-estradiol and progesterone in rat aorta are mediated by L-type Ca2+ current inhibition. Acta Pharmacol Sin 33:615-624.
8. Castillo C, Ceballos G, Rodríguez D, Villanueva C, Medina R, López J, Méndez E, and Castillo EF (2006) Effects of estradiol on phenylephrine contractility associated with intracellular calcium release in rat aorta. Am J Physiol Cell Physiol 291: C1388-C1394.
9. Chakrabarti S, Morton JS, and Davidge ST (2014) Mechanisms of estrogen effects on the endothelium: an overview. Can J Cardiol 30:705-712.
10. Chen W and Khalil RA (2008) Differential [Ca2+]i signaling of vasoconstriction in mesenteric microvessels of normal and reduced uterine perfusion pregnant rats. Am J Physiol Regul Integr Comp Physiol 295:R1962-R1972.
11. Chrissobolis S, Budzyn K, Marley PD, and Sobey CG (2004) Evidence that estrogen suppresses rho-kinase function in the cerebral circulation in vivo. Stroke 35:2200-2205.
12. Christensen KL and Mulvany MJ (1993) Mesenteric arcade arteries contribute substantially to vascular resistance in conscious rats. J Vasc Res 30:73-79.
13. Christou HA and Khalil RA (2010) Sex hormones and vascular protection in pulmonary arterial hypertension. J Cardiovasc Pharmacol 56:471-474.
14. Crane GJ, Gallagher N, Dora KA, and Garland CJ (2003) Small- and intermediateconductance calcium-activated K1 channels provide different facets of endothelium-dependent hyperpolarization in rat mesenteric artery. J Physiol 553:183-189.
15. Crews JK and Khalil RA (1999) Antagonistic effects of 17 beta-estradiol, progesterone, and testosterone on Ca2+ entry mechanisms of coronary vasoconstriction. Arterioscler Thromb Vasc Biol 19:1034-1040.
16. D'Angelo G and Osol G (1993) Regional variation in resistance artery diameter responses to alpha-adrenergic stimulation during pregnancy. Am J Physiol 264: H78-H85.
17. Dallas A and Khalil RA (2003) Ca2+ antagonist-insensitive coronary smooth muscle contraction involves activation of epsilon-protein kinase C-dependent pathway. Am J Physiol Cell Physiol 285:C1454-C1463.
18. Dalle Lucca JJ, Adeagbo AS, and Alsip NL (2000a) Influence of oestrous cycle and pregnancy on the reactivity of the rat mesenteric vascular bed. Hum Reprod 15:961-968.
19. Dalle Lucca JJ, Adeagbo AS, and Alsip NL (2000b) Oestrous cycle and pregnancy alter the reactivity of the rat uterine vasculature. Hum Reprod 15:2496-2503.
20. Darkow DJ, Lu L, and White RE (1997) Estrogen relaxation of coronary artery smooth muscle is mediated by nitric oxide and cGMP. Am J Physiol 272: H2765-H2773.
21. Dubey RK, Imthurn B, Zacharia LC, and Jackson EK (2004) Hormone replacement therapy and cardiovascular disease: what went wrong and where do we go from here? Hypertension 44:789-795.
22. Félétou M and Vanhoutte PM (2009) EDHF: an update. Clin Sci (Lond) 117:139-155.
23. Filardo EJ, Quinn JA, Bland KI, and Frackelton AR, Jr (2000) Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 14:1649-1660.
24. Freay AD, Curtis SW, Korach KS, and Rubanyi GM (1997) Mechanism of vascular smooth muscle relaxation by estrogen in depolarized rat and mouse aorta. Role of nuclear estrogen receptor and Ca2+ uptake. Circ Res 81:242-248.
25. Ghatta S, Nimmagadda D, Xu X, and O'Rourke ST (2006) Large-conductance, calcium-activated potassium channels: structural and functional implications. Pharmacol Ther 110:103-116.
26. Greenstein D, Jeffcote N, Ilsley D, and Kester RC (1996) The menstrual cycle and Raynaud's phenomenon. Angiology 47:427-436.
27. Gurney EP, Nachtigall MJ, Nachtigall LE, and Naftolin F (2014) The Women's Health Initiative trial and related studies: 10 years later: a clinician's view. J Steroid Biochem Mol Biol 142:4-11.
28. Haas E, Bhattacharya I, Brailoiu E, Damjanović M, Brailoiu GC, Gao X, Mueller-Guerre L, Marjon NA, Gut A, and Minotti R, et al. (2009) Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ Res 104:288-291.
29. Han G, Yu X, Lu L, Li S, Ma H, Zhu S, Cui X, and White RE (2006) Estrogen receptor alpha mediates acute potassium channel stimulation in human coronary artery smooth muscle cells. J Pharmacol Exp Ther 316:1025-1030.
30. Harrington WR, Sheng S, Barnett DH, Petz LN, Katzenellenbogen JA, and Katzenellenbogen BS (2003) Activities of estrogen receptor alpha- and betaselective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol Cell Endocrinol 206:13-22.
31. Herrington DM, Braden GA, Williams JK, and Morgan TM (1994) Endothelialdependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am J Cardiol 73:951-952.
32. Hiroki J, Shimokawa H, Mukai Y, Ichiki T, and Takeshita A (2005) Divergent effects of estrogen and nicotine on Rho-kinase expression in human coronary vascular smooth muscle cells. Biochem Biophys Res Commun 326:154-159.
33. Howard BV and Rossouw JE (2013) Estrogens and cardiovascular disease risk revisited: the Women's Health Initiative. Curr Opin Lipidol 24:493-499.
34. Kanashiro CA and Khalil RA (2001) Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle. Am J Physiol Cell Physiol 280: C34-C45.
35. Kanmura Y, Itoh T, and Kuriyama H (1984) Agonist actions of Bay K 8644, a dihydropyridine derivative, on the voltage-dependent calcium influx in smooth muscle cells of the rabbit mesenteric artery. J Pharmacol Exp Ther 231:717-723.
36. Keung W, Chan ML, Ho EY, Vanhoutte PM, and Man RY (2011) Non-genomic activation of adenylyl cyclase and protein kinase G by 17β-estradiol in vascular smooth muscle of the rat superior mesenteric artery. Pharmacol Res 64:509-516.
37. Keung W, Vanhoutte PM, and Man RY (2005) Acute impairment of contractile responses by 17beta-estradiol is cAMP and protein kinase G dependent in vascular smooth muscle cells of the porcine coronary arteries. Br J Pharmacol 144:71-79.
38. Khalil RA (2013) Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease. Biochem Pharmacol 86:1627-1642.
39. Khalil RA and van Breemen C (1990) Intracellular free calcium concentration/force relationship in rabbit inferior vena cava activated by norepinephrine and high K1. Pflugers Arch 416:727-734.
40. Kleuser B, Malek D, Gust R, Pertz HH, and Potteck H (2008) 17-Beta-estradiol inhibits transforming growth factor-beta signaling and function in breast cancer cells via activation of extracellular signal-regulated kinase through the G proteincoupled receptor 30. Mol Pharmacol 74:1533-1543.
41. Lahm T, Patel KM, Crisostomo PR, Markel TA, Wang M, Herring C, and Meldrum DR (2007) Endogenous estrogen attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction: the effects of sex and menstrual cycle. Am J Physiol Endocrinol Metab 293:E865-E871.
42. Lincoln TM, Cornwell TL, and Taylor AE (1990) cGMP-dependent protein kinase mediates the reduction of Ca2+ by cAMP in vascular smooth muscle cells. Am J Physiol 258:C399-C407.
43. Lindsey SH, Carver KA, Prossnitz ER, and Chappell MC (2011) Vasodilation in response to the GPR30 agonist G-1 is not different from estradiol in the mRen2. Lewis female rat. J Cardiovasc Pharmacol 57:598-603.
44. Lindsey SH, da Silva AS, Silva MS, and Chappell MC (2013) Reduced vasorelaxation to estradiol and G-1 in aged female and adult male rats is associated with GPR30 downregulation. Am J Physiol Endocrinol Metab 305:E113-E118.
45. Lindsey SH, Liu L, and Chappell MC (2014) Vasodilation by GPER in mesenteric arteries involves both endothelial nitric oxide and smooth muscle cAMP signaling. Steroids 81:99-102.
46. Ma Y, Qiao X, Falone AE, Reslan OM, Sheppard SJ, and Khalil RA (2010) Gender-specific reduction in contraction is associated with increased estrogen receptor expression in single vascular smooth muscle cells of female rat. Cell Physiol Biochem 26:457-470.
47. MacGregor EA, Frith A, Ellis J, Aspinall L, and Hackshaw A (2006) Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology 67:2154-2158.
48. Mazzuca MQ, Dang Y, and Khalil RA (2013) Enhanced endothelin receptor type B-mediated vasodilation and underlying [Ca2+]i in mesenteric microvessels of pregnant rats. Br J Pharmacol 169:1335-1351.
49. Mazzuca MQ, Li W, Reslan OM, Yu P, Mata KM, and Khalil RA (2014) Down-regulation of microvascular endothelial type B endothelin receptor is a central vascular mechanism in hypertensive pregnancy. Hypertension 64:632-643.
50. Mazzuca MQ, Wlodek ME, Dragomir NM, Parkington HC, and Tare M (2010) Uteroplacental insufficiency programs regional vascular dysfunction and alters arterial stiffness in female offspring. J Physiol 588:1997-2010.
51. Mendelsohn ME (2002) Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol 90:3F-6F.
52. Meyer MR, Baretella O, Prossnitz ER, and Barton M (2010) Dilation of epicardial coronary arteries by the G protein-coupled estrogen receptor agonists G-1 and ICI 182,780. Pharmacology 86:58-64.
53. Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, and Katzenellenbogen JA (2001) Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem 44:4230-4251.
54. Murata T, Dietrich HH, Xiang C, and Dacey RG, Jr (2013) G protein-coupled estrogen receptor agonist improves cerebral microvascular function after hypoxia/reoxygenation injury in male and female rats. Stroke 44:779-785.
55. Murphy JG and Khalil RA (1999) Decreased [Ca(21)](i) during inhibition of coronary smooth muscle contraction by 17beta-estradiol, progesterone, and testosterone. J Pharmacol Exp Ther 291:44-52.
56. Murphy JG and Khalil RA (2000) Gender-specific reduction in contractility and [Ca(21)](i) in vascular smooth muscle cells of female rat. Am J Physiol Cell Physiol 278:C834-C844.
57. Orshal JM and Khalil RA (2004) Gender, sex hormones, and vascular tone. Am J Physiol Regul Integr Comp Physiol 286:R233-R249.
58. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, Chambon P, and Mendelsohn ME (2002) Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res 90:1087-1092.
59. Raffetto JD, Ross RL, and Khalil RA (2007) Matrix metalloproteinase 2-induced venous dilation via hyperpolarization and activation of K+ channels: relevance to varicose vein formation. J Vasc Surg 45:373-380.
60. Ramírez-Rosas MB, Cobos-Puc LE, Sánchez-López A, Gutiérrez-Lara EJ, and Centurión D (2014) Pharmacological characterization of the mechanisms involved in the vasorelaxation induced by progesterone and 17β-estradiol on isolated canine basilar and internal carotid arteries. Steroids 89:33-40.
61. Reslan OM and Khalil RA (2012) Vascular effects of estrogenic menopausal hormone therapy. Rev Recent Clin Trials 7:47-70.
62. Reslan OM, Yin Z, do Nascimento GR, and Khalil RA (2013) Subtype-specific estrogen receptor-mediated vasodilator activity in the cephalic, thoracic, and abdominal vasculature of female rat. J Cardiovasc Pharmacol 62:26-40.
63. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, and Prossnitz ER (2005) A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307:1625-1630.
64. Rosano GM, Collins P, Kaski JC, Lindsay DC, Sarrel PM, and Poole-Wilson PA (1995) Syndrome X in women is associated with oestrogen deficiency. Eur Heart J 16:610-614.
65. Rosenfeld CR, White RE, Roy T, and Cox BE (2000) Calcium-activated potassium channels and nitric oxide coregulate estrogen-induced vasodilation. Am J Physiol Heart Circ Physiol 279:H319-H328.
66. Sandow SL, Senadheera S, Bertrand PP, Murphy TV, and Tare M (2012) Myoendothelial contacts, gap junctions, and microdomains: anatomical links to function? Microcirculation 19:403-415.
67. Schubert R, Lidington D, and Bolz SS (2008) The emerging role of Ca2+ sensitivity regulation in promoting myogenic vasoconstriction. Cardiovasc Res 77:8-18.
68. Smiley DA and Khalil RA (2009) Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels. Curr Med Chem 16:1863-1887.
69. Stauffer SR, Coletta CJ, Tedesco R, Nishiguchi G, Carlson K, Sun J, Katzenellenbogen BS, and Katzenellenbogen JA (2000) Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J Med Chem 43:4934-4947.
70. Stennett AK, Qiao X, Falone AE, Koledova VV, and Khalil RA (2009) Increased vascular angiotensin type 2 receptor expression and NOS-mediated mechanisms of vascular relaxation in pregnant rats. Am J Physiol Heart Circ Physiol 296:H745-H755.
71. Sun J, Meyers MJ, Fink BE, Rajendran R, Katzenellenbogen JA, and Katzenellenbogen BS (1999) Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Endocrinology 140:800-804.
72. Teoh H and Man RY (2000) Enhanced relaxation of porcine coronary arteries after acute exposure to a physiological level of 17beta-estradiol involves non-genomic mechanisms and the cyclic AMP cascade. Br J Pharmacol 129:1739-1747.
73. Tofovic SP, Jones TJ, Bilan VP, Jackson EK, and Petrusevska G (2010) Synergistic therapeutic effects of 2-methoxyestradiol with either sildenafil or bosentan on amelioration of monocrotaline-induced pulmonary hypertension and vascular remodeling. J Cardiovasc Pharmacol 56:475-483.
74. Unemoto T, Honda H, and Kogo H (2003) Differences in the mechanisms for relaxation of aorta induced by 17beta-estradiol or progesterone between normotensive and hypertensive rats. Eur J Pharmacol 472:119-126.
75. van Drongelen J, Hooijmans CR, Lotgering FK, Smits P, and Spaanderman ME (2012) Adaptive changes of mesenteric arteries in pregnancy: a meta-analysis. Am J Physiol Heart Circ Physiol 303:H639-H657.
76. Weiser MJ, Wu TJ, and Handa RJ (2009) Estrogen receptor-beta agonist diarylpropionitrile: biological activities of R- and S-enantiomers on behavior and hormonal response to stress. Endocrinology 150:1817-1825.
77. White RE, Darkow DJ, and Lang JL (1995) Estrogen relaxes coronary arteries by opening BKCa channels through a cGMP-dependent mechanism. Circ Res 77:936-942.
78. Wynne FL, Payne JA, Cain AE, Reckelhoff JF, and Khalil RA (2004) Age-related reduction in estrogen receptor-mediated mechanisms of vascular relaxation in female spontaneously hypertensive rats. Hypertension 43:405-412.
79. Yang E, Jeon SB, Baek I, Chen ZA, Jin Z, and Kim IK (2009) 17beta-estradiol attenuates vascular contraction through inhibition of RhoA/Rho kinase pathway. Naunyn Schmiedebergs Arch Pharmacol 380:35-44.
80. Yang XP and Reckelhoff JF (2011) Estrogen, hormonal replacement therapy and cardiovascular disease. Curr Opin Nephrol Hypertens 20:133-138.
81. Yener T, Turkkani Tunc A, Aslan H, Aytan H, and Cantug Caliskan A (2007) Determination of oestrous cycle of the rats by direct examination: how reliable? Anat Histol Embryol 36:75-77.
82. Yu X, Li F, Klussmann E, Stallone JN, and Han G (2014) G protein-coupled estrogen receptor 1 mediates relaxation of coronary arteries via cAMP/PKA-dependent activation of MLCP. Am J Physiol Endocrinol Metab 307:E398-E407.
83. Yu X, Ma H, Barman SA, Liu AT, Sellers M, Stallone JN, Prossnitz ER, White RE, and Han G (2011) Activation of G protein-coupled estrogen receptor induces endothelium-independent relaxation of coronary artery smooth muscle. Am J Physiol Endocrinol Metab 301:E882-E888.
84. Zhang F, Ram JL, Standley PR, and Sowers JR (1994) 17 beta-estradiol attenuates voltage-dependent Ca2+ currents in A7r5 vascular smooth muscle cell line. Am J Physiol 266:C975-C980.
85. Zhu Y, Bian Z, Lu P, Karas RH, Bao L, Cox D, Hodgin J, Shaul PW, Thoren P, and Smithies O, et al. (2002) Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science 295:505-508.